Clinical trials: Generalized Anxiety Disorder (GAD)
Irritable Bowel Syndrome, Generalized Anxiety Disorder
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder
The investigators propose to evaluate the effectiveness of duloxetine in treating subjects with both Irritable Bowel Syndrome (IBS) and Generalized Anxiety Disorder (GAD).
- Trial name
- NCT00961298
- Testing
- Duloxetine
- Volunteers
- 17 people
- Sponsor
- West Penn Allegheny Health System
Pharmacokinetics
A Phased Clinical Trial of Dietary Supplemental Kava: Kava Pharmacokinetics
Kava is a dietary supplement on the US market and is experiencing a resurgence of its use. Its pharmacokinetic information, however, is lacking which is important for its future effective usage as a dietary supplement or…
- Trial name
- KavaPK (NCT03843502)
- Testing
- Kava Dietary Supplement
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Florida
Diabetes Mellitus, Type 1
GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)
The objectives of the main study is to: Evaluate the safety of giving GAD-Alum (Glutamic acid decarboxylase) (Diamyd) directly into lymph glands in combination with an oral vitamin D regimen Evaluate how the above mentioned…
- Trial name
- DIAGNODE (NCT02352974)
- Testing
- GAD-Alum, Vitamin D
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Johnny Ludvigsson
Generalized Anxiety Disorder
Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD) is an anxiety disorder characterized by excessive and uncontrollable worry. Our research group has developed a cognitive-behavioural treatment (CBT) for GAD centered upon intolerance of…
- Trial name
- NCT01958788
- Testing
- Cognitive-Behavioural Treatment
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Concordia University, Montreal
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Anxiety
Youth Mayo Clinic Anxiety Coach Pilot Study
This research study aims to test the feasibility and effectiveness of using the Mayo Clinic Anxiety Coach smartphone app as an addition to traditional therapy for the treatment of anxiety disorders in youth, particularly those…
- Trial name
- NCT02205177
- Testing
- Mayo Clinic Anxiety Coach
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stephen Whiteside
Generalized Anxiety Disorder
Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects
Current therapies for Generalized Anxiety Disorder (GAD) have limited effectiveness. This study measures the efficacy of two different approaches to reducing anxiety and stress.
- Trial name
- NCT01033851
- Testing
- Mindfulness Based Stress Reduction, Stress Management Education
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Massachusetts General Hospital
Pharmacokinetics
Biomarker Changes and Anxiolytic Effects-Phase 2
This study will examine the utility of plasma and urinary based biomarkers for the anxiolytic properties of kava. The investigators will conduct a one week, double blind, randomized placebo controlled trial of kava, dosed at…
- Trial name
- KavaPK (NCT04565145)
- Testing
- Kava Dietary Supplement
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Florida
Depression, Generalized Anxiety Disorder
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
For this trial, the investigators propose a prospective trial of a collaborative care program to identify and treat depression, generalized anxiety disorder, and panic disorder among patients admitted to the hospital for an acute…
- Conditions
- Depression, Generalized Anxiety Disorder, Panic Disorder
- Trial name
- MOSAIC (NCT01201967)
- Testing
- Collaborative care, Usual care
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 1, Prediabetic State
Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies
The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD (Diamyd), in combination with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes in…
- Trial name
- DiAPREV-IT2 (NCT02387164)
- Testing
- Alum-GAD, Vitamin D3
- Where
- Sweden
- Volunteers
- 26 people
- Sponsor
- Lund University
Schizophrenia, Stress Disorders, Post-Traumatic
Optimizing Cognitive Remediation
Veterans with mental illness face challenges with community reintegration, including achieving vocational success, attaining their educational goals and going back to school, and maintaining a high quality of life.
- Conditions
- Schizophrenia, Stress Disorders, Post-Traumatic, Generalized Anxiety Disorder, Mood Disorders
- Trial name
- NCT04395157
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Alcoholism, Generalized Anxiety Disorder
Levetiracetam for the Treatment of Alcohol Dependence and Anxiety
The purpose of this study is to determine if levetiracetam is effective in treating alcohol dependence in patients with anxiety symptoms.
- Conditions
- Alcoholism, Generalized Anxiety Disorder, Panic Disorder, Social Phobia
- Trial name
- NCT00141115
- Testing
- levetiracetam
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- New York State Psychiatric Institute
Generalized Anxiety Disorder, Bipolar Disorder
Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder
This study proposes to examine the potential safety and efficacy of ziprasidone for patients with anxiety and bipolar disorder on anxiety outcomes, bipolar symptoms, and on measures of quality of life and resilience.
- Trial name
- NCT00374543
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
Generalized Anxiety Disorder
Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.
- Trial name
- NCT00730691
- Testing
- Vortioxetine, Duloxetine
- Where
- 66 sites in United States
- Volunteers
- 781 people
- Sponsor
- Takeda
Generalized Anxiety Disorder
Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder
We are investigating the feasibility and efficacy of transcranial magnetic stimulation (TMS) for patients with GAD who were placebo nonresponders in DIEF003523.1.
- Trial name
- NCT01815099
- Testing
- rTMS Treatment
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Generalized Anxiety Disorder
Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults
This study will assess whether adding cognitive behavioral therapy to the antidepressant escitalopram is effective in reducing anxiety in older adults with generalized anxiety disorder.
- Trial name
- NCT00601965
- Testing
- Escitalopram, Cognitive behavioral therapy (CBT)
- Where
- 3 sites in United States
- Volunteers
- 73 people
- Sponsor
- Veterans Medical Research Foundation
Generalized Anxiety Disorder
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.
- Trial name
- NCT00734071
- Testing
- Vortioxetine
- Where
- 33 sites in United States
- Volunteers
- 304 people
- Sponsor
- Takeda
Obsessive-Compulsive Disorder, Generalized Anxiety Disorder
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
The objective of this study was to obtain preliminary open-label data on the efficacy and tolerability of memantine, an anti-glutamatergic medication with a unique pharmacodynamic profile, in individuals with OCD and individuals…
- Trial name
- NCT00674219
- Testing
- Memantine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
- Trial name
- VLZ-MD-06 (NCT01766401)
- Testing
- Vilazadone
- Where
- 30 sites in United States
- Volunteers
- 402 people
- Sponsor
- Forest Laboratories
Generalized Anxiety Disorder
Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
The purpose of this study is to find out how an anti-anxiety drug or placebo affects the activity of your brain when you are at rest and when you are viewing emotional material, such as, emotional faces and pictures.
- Trial name
- GAD (NCT00662259)
- Testing
- Alprazolam (Xanax)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego